title: Belimumab for the treatment of refractory systemic lupus erythematosus: real-life experience in the first year of use in 18 Italian patients.
authors.forename: Laura
authors.initials: L
authors.lastname: Andreoli
authors.forename: Rossella
authors.initials: R
authors.lastname: Reggia
authors.forename: Lara
authors.initials: L
authors.lastname: Pea
authors.forename: Micol
authors.initials: M
authors.lastname: Frassi
authors.forename: Alessandra
authors.initials: A
authors.lastname: Zanola
authors.forename: Stefania
authors.initials: S
authors.lastname: Cartella
authors.forename: Franco
authors.initials: F
authors.lastname: Franceschini
authors.forename: Angela
authors.initials: A
authors.lastname: Tincani
mesh_terms: D061605:Administration, Intravenous; D000328:Adult; D000974:Antibodies, Antinuclear / Q000097:blood; D017152:Antibodies, Antiphospholipid / Q000097:blood; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D016903:Drug Monitoring; D004359:Drug Therapy, Combination / Q000379:methods; D005260:Female; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects; D007558:Italy; D008180:Lupus Erythematosus, Systemic / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology; D062072:Patient Acuity; D016896:Treatment Outcome
chemical_list: D000974:Antibodies, Antinuclear; D017152:Antibodies, Antiphospholipid; D061067:Antibodies, Monoclonal, Humanized; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; C511911:belimumab